BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18383321)

  • 1. Bone marrow glycophorin-positive erythroid cells of myelodysplastic patients responding to high-dose rHuEPO therapy have a different gene expression pattern from those of nonresponders.
    Cortelezzi A; Colombo G; Pellegrini C; Silvestris I; Moronetti Mazzeo L; Bosari S; Lambertenghi Deliliers G; Fracchiolla NS
    Am J Hematol; 2008 Jul; 83(7):531-9. PubMed ID: 18383321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes.
    Stasi R; Brunetti M; Bussa S; Conforti M; Di Giulio C; Crescenzi A; Terzoli E; Vecchione A; Pagano A
    Clin Cancer Res; 1997 May; 3(5):733-9. PubMed ID: 9815743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Transcriptome profiling of marrow mononuclear cells of patients with myelodysplastic syndrome using cDNA microarray analysis].
    Qian J; Chen ZX; Wang W; Cen JN; Xue YQ
    Zhonghua Yi Xue Za Zhi; 2004 Aug; 84(15):1260-4. PubMed ID: 15387962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
    Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
    Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for downregulation of erythropoietin receptor in bone marrow erythroid cells of patients with chronic idiopathic neutropenia.
    Pontikoglou C; Liapakis G; Pyrovolaki K; Papadakis M; Bux J; Eliopoulos GD; Papadaki HA
    Exp Hematol; 2006 Oct; 34(10):1312-22. PubMed ID: 16982324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
    Maratheftis CI; Bolaraki PE; Voulgarelis M
    Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome.
    Hofmann WK; Takeuchi S; Takeuchi N; Thiel E; Hoelzer D; Koeffler HP
    Leuk Res; 2006 Nov; 30(11):1347-53. PubMed ID: 16682076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiling of the bone marrow mononuclear cells from patients with myelodysplastic syndrome.
    Qian J; Chen Z; Wang W; Cen J; Xue Y
    Oncol Rep; 2005 Nov; 14(5):1189-97. PubMed ID: 16211284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A statistical pattern recognition approach for determining cellular viability and lineage phenotype in cultured cells and murine bone marrow.
    Quinn J; Fisher PW; Capocasale RJ; Achuthanandam R; Kam M; Bugelski PJ; Hrebien L
    Cytometry A; 2007 Aug; 71(8):612-24. PubMed ID: 17542025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of MDS patients with recombinant human erythropoietin and the role of GSTs.
    Tsabouri SE; Georgiou I; Katsaraki A; Bourantas KL
    J Exp Clin Cancer Res; 2004 Sep; 23(3):417-24. PubMed ID: 15595630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited numbers of apoptotic cells in fresh paraffin embedded bone marrow samples of patients with myelodysplastic syndrome.
    Brada SJ; van de Loosdrecht AA; Koudstaal J; de Wolf JT; Vellenga E
    Leuk Res; 2004 Sep; 28(9):921-5. PubMed ID: 15234568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report.
    Clavio M; Nobili F; Balleari E; Girtler N; Ballerini F; Vitali P; Rosati P; Venturino C; Varaldo R; Gobbi M; Ghio R; Rodriguez G
    Eur J Haematol; 2004 Feb; 72(2):113-20. PubMed ID: 14962248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
    Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
    Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Application of bioinformatics analysis to optimize amifostine combination therapeutic regimen of myelodysplastic syndrome].
    Lu XC; Yang B; Zhu HL; Fan H; Li SX; Liu Y; Yao SQ
    Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(26):1834-7. PubMed ID: 19953928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations.
    Tehranchi R; Fadeel B; Schmidt-Mende J; Forsblom AM; Emanuelsson E; Jadersten M; Christensson B; Hast R; Howe RB; Samuelsson J; Zhivotovsky B; Hellström-Lindberg E
    Clin Cancer Res; 2005 Sep; 11(17):6291-9. PubMed ID: 16144933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of defects in the transcriptional program during lineage-specific in vitro differentiation of CD34(+) cells selected from patients with both low- and high-risk myelodysplastic syndrome.
    Gueller S; Komor M; Nowak D; Baldus CD; de Vos S; Hoelzer D; Ottmann OG; Hofmann WK
    Exp Hematol; 2010 Sep; 38(9):718-32, 732.e1-6. PubMed ID: 20621626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: a hypothesis supported by unique case reports.
    Valent P
    Leuk Res; 2008 Sep; 32(9):1333-7. PubMed ID: 18417212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes.
    Ferrero D; Darbesio A; Giai V; Genuardi M; Dellacasa CM; Sorasio R; Bertini M; Boccadoro M
    Br J Haematol; 2009 Feb; 144(3):342-9. PubMed ID: 19036104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Dlk1 gene in myelodysplastic syndrome determined by microarray, and its effects on leukemia cells.
    Qi X; Chen Z; Liu D; Cen J; Gu M
    Int J Mol Med; 2008 Jul; 22(1):61-8. PubMed ID: 18575777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.